Monograph Details
|
|
Infections & Infestations
> Viral infections
|
|
RETROVIR TABLETS |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Nucleoside analogue (reverse transcriptase inhibitor). |
| Generic Name |
|
Zidovudine 300mg. |
| Also |
• RETROVIR CAPSULES
• RETROVIR IV
• RETROVIR SYRUP
|
| Indications |
|
HIV infection. Prevention of maternal-fetal HIV transmission. |
| Children |
|
<6 weeks and/or for vertical transmission: see literature. 6 weeks–12 years: 160mg/m2 (max 200mg) every 8 hours. |
| Adults |
|
600mg daily in divided doses. End-stage renal disease on dialysis: 100mg every 6–8 hours. Vertical transmission: see literature. |
| Contraindications |
|
Concomitant other forms of zidovudine. |
| Precautions |
|
Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Monitor for hematologic toxicity; reduce dose or suspend if significant anemia and/or granulocytopenia occurs; transfuse if necessary. Renal or hepatic dysfunction: consider reducing dose. Bone marrow suppression. Risk of liver disease. Women, obesity, prolonged nucleoside exposure, or advanced HIV disease: increased risk of toxicity. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Avoid stavudine, doxorubicin, ribavirin, other nucleoside analogues. Caution with other nephrotoxic, cytotoxic, myelosuppressive drugs (eg, dapsone, flucytosine, vincristine, vinblastine, adriamycin, ganciclovir, interferon-alpha), methadone, acyclovir. Fluconazole, atovaquone, probenecid, valproic acid increase zidovudine levels. Monitor phenytoin. May be antagonized by rifampin, phenytoin, other CYP450 inducers. Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin. |
| Adverse Reactions |
|
Anemia, neutropenia, headache, malaise, GI disturbances, insomnia, pain, myopathy, neuropathy, myositis, thrombocytopenia, lactic acidosis, steatosis, hepatomegaly, fat redistribution, pancreatitis, others. |
| Extra Text |
|
Note: Register pregnant patients exposed to zidovudine by calling (800) 258-4263. |
| How Supplied |
Caps—100
Tabs—60
Syrup—240mL
IV (20mL/vial)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
